vs
Offerpad Solutions Inc.（OPAD）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Offerpad Solutions Inc.的1.1倍（$127.1M vs $114.1M），再鼎医药同比增速更快（17.1% vs -34.5%），Offerpad Solutions Inc.自由现金流更多（$65.7M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -36.8%）
Offerpad Solutions Inc是美国知名房地产科技企业，专注于简化住宅房产交易流程，采用iBuyer模式直接向卖家收购房屋，完成翻新后挂牌出售，同时提供按揭、产权服务、灵活搬迁方案等配套服务，业务覆盖美国数十个州。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
OPAD vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.1倍
$114.1M
营收增速更快
ZLAB
高出51.6%
-34.5%
自由现金流更多
OPAD
多$92.4M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-36.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $127.1M |
| 净利润 | — | — |
| 毛利率 | 7.0% | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | — | — |
| 营收同比 | -34.5% | 17.1% |
| 净利润同比 | 49.1% | — |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OPADZLAB
| Q4 25 | $114.1M | $127.1M | ||
| Q3 25 | $132.7M | $115.4M | ||
| Q2 25 | $160.3M | $109.1M | ||
| Q1 25 | $160.7M | $105.7M | ||
| Q4 24 | $174.3M | $108.5M | ||
| Q3 24 | $208.1M | $101.8M | ||
| Q2 24 | $251.1M | $100.1M | ||
| Q1 24 | $285.4M | $87.1M |
净利润OPADZLAB
| Q4 25 | — | — | ||
| Q3 25 | $-11.6M | $-36.0M | ||
| Q2 25 | $-10.9M | $-40.7M | ||
| Q1 25 | $-15.1M | $-48.4M | ||
| Q4 24 | $-17.3M | — | ||
| Q3 24 | $-13.5M | $-41.7M | ||
| Q2 24 | $-13.8M | $-80.3M | ||
| Q1 24 | $-17.5M | $-53.5M |
毛利率OPADZLAB
| Q4 25 | 7.0% | 51.0% | ||
| Q3 25 | 7.0% | 59.5% | ||
| Q2 25 | 8.9% | 60.6% | ||
| Q1 25 | 6.5% | 63.6% | ||
| Q4 24 | 6.1% | 61.5% | ||
| Q3 24 | 8.2% | 64.1% | ||
| Q2 24 | 8.7% | 64.9% | ||
| Q1 24 | 7.9% | 61.4% |
营业利润率OPADZLAB
| Q4 25 | — | -54.6% | ||
| Q3 25 | -5.1% | -42.3% | ||
| Q2 25 | -4.9% | -50.3% | ||
| Q1 25 | -7.2% | -53.3% | ||
| Q4 24 | -7.8% | -62.6% | ||
| Q3 24 | -4.3% | -66.6% | ||
| Q2 24 | -3.9% | -76.0% | ||
| Q1 24 | -4.8% | -80.7% |
净利率OPADZLAB
| Q4 25 | — | — | ||
| Q3 25 | -8.7% | -31.2% | ||
| Q2 25 | -6.8% | -37.3% | ||
| Q1 25 | -9.4% | -45.8% | ||
| Q4 24 | -9.9% | — | ||
| Q3 24 | -6.5% | -40.9% | ||
| Q2 24 | -5.5% | -80.2% | ||
| Q1 24 | -6.1% | -61.4% |
每股收益（稀释后）OPADZLAB
| Q4 25 | — | $-0.05 | ||
| Q3 25 | $-0.37 | $-0.03 | ||
| Q2 25 | $-0.39 | $-0.04 | ||
| Q1 25 | $-0.55 | $-0.04 | ||
| Q4 24 | $-0.64 | $-0.09 | ||
| Q3 24 | $-0.49 | $-0.04 | ||
| Q2 24 | $-0.50 | $-0.08 | ||
| Q1 24 | $-0.64 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $26.5M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $38.2M | $715.5M |
| 总资产 | $154.8M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OPADZLAB
| Q4 25 | $26.5M | $689.6M | ||
| Q3 25 | $31.0M | $717.2M | ||
| Q2 25 | $22.6M | $732.2M | ||
| Q1 25 | $30.8M | $757.3M | ||
| Q4 24 | $43.0M | $779.7M | ||
| Q3 24 | $48.5M | $616.1M | ||
| Q2 24 | $56.9M | $630.0M | ||
| Q1 24 | $68.5M | $650.8M |
股东权益OPADZLAB
| Q4 25 | $38.2M | $715.5M | ||
| Q3 25 | $39.9M | $759.9M | ||
| Q2 25 | $24.5M | $791.7M | ||
| Q1 25 | $34.2M | $810.8M | ||
| Q4 24 | $47.7M | $840.9M | ||
| Q3 24 | $64.7M | $667.7M | ||
| Q2 24 | $77.6M | $704.2M | ||
| Q1 24 | $88.1M | $762.2M |
总资产OPADZLAB
| Q4 25 | $154.8M | $1.2B | ||
| Q3 25 | $223.5M | $1.2B | ||
| Q2 25 | $268.0M | $1.2B | ||
| Q1 25 | $274.5M | $1.2B | ||
| Q4 24 | $313.1M | $1.2B | ||
| Q3 24 | $338.5M | $985.3M | ||
| Q2 24 | $406.6M | $987.4M | ||
| Q1 24 | $369.7M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $66.8M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $65.7M | $-26.7M |
| 自由现金流率自由现金流/营收 | 57.6% | -21.0% |
| 资本支出强度资本支出/营收 | 0.9% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流OPADZLAB
| Q4 25 | $66.8M | $-26.0M | ||
| Q3 25 | $40.0M | $-32.0M | ||
| Q2 25 | $-13.5M | $-31.0M | ||
| Q1 25 | $-10.2M | $-61.7M | ||
| Q4 24 | $20.8M | $-55.8M | ||
| Q3 24 | $39.6M | $-26.8M | ||
| Q2 24 | $-54.4M | $-42.2M | ||
| Q1 24 | $2.4M | $-90.1M |
自由现金流OPADZLAB
| Q4 25 | $65.7M | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | $-13.6M | $-33.9M | ||
| Q1 25 | $-11.2M | $-63.2M | ||
| Q4 24 | $15.4M | $-58.4M | ||
| Q3 24 | $38.7M | $-28.2M | ||
| Q2 24 | $-54.4M | $-42.9M | ||
| Q1 24 | $2.0M | $-91.1M |
自由现金流率OPADZLAB
| Q4 25 | 57.6% | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | -8.5% | -31.1% | ||
| Q1 25 | -7.0% | -59.9% | ||
| Q4 24 | 8.9% | -53.8% | ||
| Q3 24 | 18.6% | -27.7% | ||
| Q2 24 | -21.7% | -42.9% | ||
| Q1 24 | 0.7% | -104.5% |
资本支出强度OPADZLAB
| Q4 25 | 0.9% | 0.5% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.1% | 2.6% | ||
| Q1 25 | 0.6% | 1.5% | ||
| Q4 24 | 3.1% | 2.4% | ||
| Q3 24 | 0.4% | 1.3% | ||
| Q2 24 | 0.0% | 0.7% | ||
| Q1 24 | 0.1% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OPAD
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
